OPTN Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of OptiNose, to Paratek Pharmaceuticals

MONSEY, N.Y., March 20, 2025 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of OptiNose, Inc. (Nasdaq: OPTN) (“OptiNose”) to Paratek Pharmaceuticals (“Paratek”) for $9.00 per share in cash, plus a contingent value right (“CVR”) worth$5.00 per share payable in the event that certain net revenue milestones are achieved by OptiNose’s flagship drug, XHANCE. Notably, as detailed below, the sale price is below the price target for OptiNose of at least t ...